Vir Biotechnology, Inc.

With new data presented at the recent European Association for the Study of the Liver meeting, Gilead is ready to seek US approval of its hepatitis D therapy bulevirtide once again. The firm had been

When Marianne De Backer took the helm at San Francisco-based Vir Biotechnology in April 2023, the company was facing a dramatic shift in fortune. After riding high during the COVID-19 pandemic with bl

IAVI’s rVSVdeltaG-LASV-GPC, which is the first Lassa fever vaccine candidate to be evaluated in a Phase II trial, is among the first two products in 2025 to secure a place on PRIME, the European Medic

Vir Biotechnology’s move from focusing solely on antiviral drugs to incorporating oncology into its pipeline has shown early signs of potentially paying off as the company announced safety and efficac